JULY 17, 2020 - "With a foundation in our profitable pharmaceutical business, Orexo has been able to invest and act on opportunities where we are uniquely positioned to help millions of people suffering from mental illness"
OCTOBER 15 2020 - The winner of the Orexo/Lyfebulb Innovation Challenge for substance use disorder (SUD) is announced. The well-renowned jury selected Rohan Dixit of Lief as the winner for his innovative wearable device that by measuring heart rate variability helps reduce anxiety, which is highly correlated to SUD.
vorvida® is the first digital therapy for treatment of alcohol misuse. It is a Cognitive Behavioral Therapy (CBT) and has scientifically showed to reduce daily alcohol consumption. vorvida® is since recently available on the US market and to learn more about this unique digital therapy view below.
OCTOBER 1 2020 - View the presentation held today where Nikolaj Sørensen, CEO, Dennis Urbaniak, EVP Digital Therapeutics and Michael Sumner, Chief Medical Officer provided an update on the company´s new digital therapeutics business and also gave more insights into the scientific evidence supporting the therapies.
JUNE 30, 2020 - Preliminary results for OX125 indicate extensive and rapid absorption across all formulations as well as good tolerability, supporting the viability of OX125 as a rescue medication for opioid overdose. OX125 could be an important addition to OX124 and the results underline the applicability of Orexo’s novel intranasal drug delivery platform.